ProLynx annonce l’essai clinique de phase 1B de son agent endommageant l’ADN, PLX038 (PEG~SN-38), associé à l’inhibiteur de la PARP Rubraca® (rucaparib) au National Cancer Institute  

Matt Turner
Patient Affordability

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Daniel Sontupe
Market Access

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement